Program
ZL-1503
A development code.
Its studies are mostly in Dermatitis, Atopic, led by Zai Lab.
Who develops it
Each company that leads studies of it, as its sponsor page counts them.
| Company | Studies it leads | Furthest phase | First study | Next primary completion |
|---|---|---|---|---|
| Zai Lab | 22 open or running | phase 1since Nov 14, 2025 | Nov 14, 2025 | Feb 6, 2027phase 1 · NCT07658482 |
History and what’s ahead
From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.
- Nov 14, 2025First study: phase 1 study in Dermatitis, AtopicFirst studyNCT07235384 · 84 planned · Australia, China, New Zealand
- Jun 10, 2026Phase 1 study in Healthy VolunteersNCT07658482 · 36 planned · New Zealand
Ahead
- Feb 6, 2027Primary completion: phase 1 study in Healthy VolunteersNCT07658482
- Dec 28, 2027Primary completion: phase 1 study in Dermatitis, AtopicNCT07235384
TargetBeta
Not stated by its company or a source we have read. Most early programs say nothing of it.
Studies
All 2 led by companies developing it, newest first. Each opens its study page.
| Study | Phase | Status | Primary completion | Size |
|---|---|---|---|---|
| NCT07658482Healthy Volunteers · New Zealand | 1 | Not yet recruiting | Feb 6, 2027 | 36 |
| NCT07235384Dermatitis, Atopic · Australia, China, New Zealand | 1 | Recruiting | Dec 28, 2027 | 84 |
How it is read
Names in the registry
- “ZL-1503”, 5 entries
Codes read as this program: ZL1503.
Conditions, from the studies’ own filings
- Dermatitis, Atopic, 1 study
First seen by our ledger Nov 13, 2026.
What this can’t show
- Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
- Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
- Primary completion dates are the sponsors’ estimates and often move.
- A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.